This month hasn’t been all bad for Carlo Croce. Despite issuing two corrections and being the subject of a lengthy New York Times article about how he’s dodged misconduct accusations for years (prompting his institution to re-open an investigation), Croce is now the recipient of a prestigious award from the American Association for Cancer Research.
In a recent news release, the AACR announced it was bestowing Croce the 11th Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research, named after the CEO of the AACR, for his work in the field.
According to the news release:
The Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research was established in 2007 to recognize a true champion of cancer research whose leadership and extraordinary achievements in cancer research have had a major impact on the field. Such achievements may include scientific contributions to the acceleration of progress against cancer, significant accomplishments in the national or international awareness of the importance of cancer research, or other ways of demonstrating a sustained extraordinary commitment to cancer research.
Croce is the chair of the Department of Cancer Biology and Genetics at The Ohio State University. He’s also now under investigation at OSU after a colleague levied allegations such as plagiarism and falsified data.
By our count, Croce has five retractions (1, 2, 3, 4, 5), some of which we have covered. Some of his papers have also been questioned on PubPeer, many of which he’s coauthored with Alfredo Fusco, a cancer researcher in Italy who has nine retractions and is in the midst of an investigation for scientific misconduct.
We asked AACR if it considered the recent news about Croce before announcing its decision to give him this award. A spokesperson told us:
Dr. Carlo Croce was nominated and selected by an expert committee of his peers, and the AACR voted to move forward on the award committee’s recommendation. We are aware of the allegations made in The New York Times’ article on Dr. Croce. The AACR knows of no definitive findings that would warrant a change in this decision. Therefore, Dr. Croce will be presented with this award.
Here’s more about the AACR’s decision, from its news release about the award:
[Croce] is being recognized for his consistent and long-standing impact on the translation of fundamental cancer mechanisms to clinical applications. His many contributions to the field of cancer research have provided an important foundation for the identification of druggable targets and have been invaluable to advancements made toward cancer diagnosis and prognosis. Likewise, his research has masterfully translated chromosomal translocation breakpoints to strategies for cancer prevention, early detection, and therapy.
“Dr. Croce is a highly esteemed basic and translational cancer researcher whose paradigm-shifting work has provided the basis for intensive scientific investigations throughout the international scientific community,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “He has also provided extraordinary scientific leadership in the national and international scene, including research administration and mentorship of many talented young investigators, and he is greatly deserving of this award.”
Like Retraction Watch? Consider making a tax-deductible contribution to support our growth. You can also follow us on Twitter, like us on Facebook, add us to your RSS reader, sign up on our homepage for an email every time there’s a new post, or subscribe to our daily digest. Click here to review our Comments Policy. For a sneak peek at what we’re working on, click here.